A sensitive direct sequencing assay based on nested PCR for the detection of HBV polymerase and surface glycoprotein mutations

Journal of Virological Methods

Volumn 159, Issue 1, 2009, Pages 53-57

  Vincenti, Donatella ^a   Solmone, Mariacarmela ^a   Garbuglia, Anna Rosa ^a   Iacomi, Fabio ^a   Capobianchi, Maria Rosaria ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Antiviral resistance; Direct sequencing; HBV; Mutations; Nested PCR; Polymerase

Indexed keywords

GLYCOPROTEIN; HEPATITIS B VIRUS POLYMERASE; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENZYME;

AMPLICON; ARTICLE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B VIRUS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; SENSITIVITY ANALYSIS; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENE PRODUCTS, POL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MEMBRANE GLYCOPROTEINS; MUTATION; OPEN READING FRAMES; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; VIRAL LOAD;

HEPATITIS B VIRUS;

EID: 67349287021     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2009.02.027     Document Type: Article

References (29)

1. De Maddalena C., Giambelli C., Tanzi E., Colzani D., Schiavini M., Milazzo L., Bernini F., Sbranati E., Cargnel A., Bruno R., Galli M., and Zehender G. High level of genetic heterogeneity in S and P genes of genotype D hepatitis B virus. Virology 365 (2007) 113-124
2. Degertekin B., Hussain M., Tan J., Oberhelman K., and Lok A.S. Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J. Hepatol. 50 (2009) 42-48
3. Gintowt A.A., Germer J.J., Mitchell P.S., and Yao J.D. Evaluation of the MagNA pure LC used with the TRUGENE HBV genotyping kit. J. Clin. Virol. 34 (2005) 155-157
4. Hadziyannis S.J., Papatheodoridis G.V., Dimou E., Laras A., and Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32 (2000) 847-851
5. Hosseini S.Y., Sabahi F., Amini-Bavil-Olyaee S., Alavian S.M., and Merat S. A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains. J. Virol. Methods 137 (2006) 298-303
6. Ijaz S., Arnold C., Dervisevic S., Mechurova J., Tatman N., Tedder R.S., and Naoumov N.V. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. J. Med. Virol. 80 (2008) 1160-1170
7. Jardi R., Buti M., Rodriguez-Frias F., Cotrina M., Costa X., Pascual C., Esteban R., and Guardia J. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J. Virol. Methods 83 (1999) 181-187
8. Kessler H.H., Stelzl E., Marth E., and Stauber R.E. Detection of mutations in the hepatitis B virus polymerase gene. Clin. Chem. 49 (2003) 989-992
9. Kim H.S., Han K.H., Ahn S.H., Kim E.O., Chang H.Y., Moon M.S., Chung H.J., Yoo W., Kim S.O., and Hong S.P. Evaluation of methods for monitoring drug-resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir. Ther. 10 (2005) 441-449
10. Lampertico P., Vigano M., Vanenti E., Iavarone M., Lunghi G., and Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 4 (2005) 1414-1419
11. Li Z.G., Chen L.Y., Huang J., Qiao P., Qiu J.M., and Wang S.Q. Quantification of the relative levels of wild-type and lamivudine-resistant mutant virus in serum of HBV-infected patients using microarray. J. Viral Hepat. 12 (2005) 168-175
12. Locarnini S. Primary resistance, multidrug-resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol. Int. 2 (2008) 147-151
13. Lok A.S., Hussain M., Cursano C., Margotti M., Gramenzi A., Grazi G.L., Jovine E., Benardi M., and Andreone P. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 32 (2000) 1145-1153
14. Lok A.S., Zoulim F., Locarnini S., Bartholomeusz A., Ghany M.G., Pawlotsky J.M., Liaw Y.F., Mizokami M., Kuiken C., and Hepatitis B Virus Drug-resistance Working Group. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46 (2007) 254-265 (review)
15. Lok A.S., Zoulim F., Locarnini S., Mangia A., Niro G., Decraemer H., Maertens G., Hulstaert F., De Vreese K., and Sablon E. Monitoring drug-resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J. Clin. Microbiol. 40 (2002) 3729-3734
16. Lupo J., Larrat S., Hilleret M.N., Germi R., Boyer V., Nicod S., Barguès G., Leroy V., Seigneurin J.M., Zarski J.P., and Morand P. Assessment of selective real-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant strains and comparison with direct sequencing and line probe assays. J. Virol. Methods 156 (2009) 52-58
17. Matthews G.V., Bartholomeusz A., Locarnini S., Ayres A., Sasaduesz J., Seaberg E., Cooper D.A., Lewin S., Dore G.J., and Thio C.L. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 20 (2006) 863-870
18. Pawlotsky J.M., Dusheiko G., Hatzakis A., Lau D., Lau G., Liang T.J., Locarnini S., Martin P., Richman D.D., and Zoulim F. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 134 (2008) 405-415 (review)
19. Sablon E., and Shapiro F. Advances in molecular diagnosis of HBV infection and drug-resistance. Int. J. Med. Sci. 2 (2004) 8-16
20. Sheldon J., Rodès B., Zoulim F., Bartholomeusz A., and Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J. Viral Hepat. 13 (2006) 427-434 (review)
21. Solmone M., Vincenti D., Prosperi M.C., Bruselles A., Ippolito G., and Capobianchi M.R. Use of massively parallel ultra-deep pyrosequencing to characterize genetic diversity of HBV in drug-resistant and naïve patients and to detect minor variants in RT and HBsAg. J. Virol. (2008) 10.1128/JVI.02011-08
22. Tang X.R., Zhang J.S., Zhao H., Gong Y.H., Wang Y.Z., and Zhao J.L. Detection of hepatitis B virus genotypes using oligonucleotide chip among hepatitis B virus carriers in Eastern China. World J. Gastroenterol. 13 (2007) 1975-1979
23. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J. Clin. Virol. 25 (2002) 97-106 (review)
24. Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin. Microbiol. Rev. 20 (2007) 426-439 (review)
25. Wang R.S., Zhang H., Zhu Y.F., Han B., and Yang Z.J. Detection of YMDD mutants using universal template real-time PCR. World J. Gastroenterol. 12 (2006) 1308-1311
26. Warner N., and Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 48 (2008) 88-98
27. Weinberger K.M., Bauer T., Böhm S., and Jilg W. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J. Gen. Virol. 81 (2000) 165-1174
28. Yeon J.E. Technique for the early detection of drug-resistant HBV DNA during antiviral therapy. Intervirology 51 (2008) 7-10 (review)
29. Yuan H., and Lee W.M. Molecular mechanism of resistance to antiviral therapy patients with chronic hepatitis B. Curr. Mol. Med. 7 (2007) 185-197